On November 3, a single Bitcoin short position worth $2.02 million was liquidated on Binance's perpetual futures market at a price of $77,150. This event highlights the volatility and risk in Bitcoin futures trading, where large positions can be forcibly closed if the market moves against them. Such liquidations can impact market sentiment and price movements in the short term. Traders should remain cautious of leverage risks in crypto futures markets.
The recent $2.02 million Bitcoin short liquidation on Binance provides context for cryptocurrency market activity. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Nov 05, 2026 00:31 WIB: out of 50 priced major cryptocurrencies, 45 rose and 4 fell today. Notable movers include ALGO at Rp1.809 with a 6.29% increase and 94% buy activity, CRV at Rp5.042 with a 6.21% rise and 69% buy activity, and ETH at Rp44.060.177 with a 5.70% gain but 69% sell activity.
Goldman Sachs Group, Inc. disclosed that it briefly held a combined stake exceeding 3% in Ontex Group NV shares as of October 27, 2026, with 566,115 voting rights and 1,965,157 financial instruments. However, by October 28, 2026, their combined posit...
BNP Paribas announced its monthly declaration of voting rights and shares as of October 31, 2026. The bank reported a total of 1,101,600,607 shares and an equal number of voting rights. This update is part of regulatory compliance under French commer...
Ontex disclosed that Goldman Sachs Group, Inc. crossed the 3% ownership threshold in Ontex shares on October 27, 2026, holding a combined total of 3.07% including voting rights and financial instruments. However, the next day, October 28, 2026, Goldm...
Neion Bio has appointed John A. Maga, Ph.D., as Head of Biologics and CMC to lead the development of biologic medicines using its Raptor platform, which produces proteins in transgenic chicken eggs. Maga brings over 25 years of biopharmaceutical expe...
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
